Illumina for proteins

• Single Molecule Detection Platform: A proprietary platform designed for single molecule detection, enabling next-generation protein sequencing for use in proteomics and other life science applications.

Quantum-Si (QSI) primarily sells its advanced single-molecule detection platforms and sequencing technology to other organizations rather than individual consumers. Given the nature of their proprietary platform for next-generation protein sequencing and its application in fields like proteomics, their major customers are typically within the scientific research and life sciences sectors.

The company's primary customer categories include:

1. Academic and Government Research Institutions: Universities, national laboratories, and other publicly funded research organizations that conduct fundamental and applied research in life sciences, proteomics, and biotechnology. These institutions are often early adopters of cutting-edge scientific instrumentation.
2. Biopharmaceutical Companies: Pharmaceutical and biotechnology firms engaged in drug discovery, development, biomarker identification, target validation, and other R&D activities where detailed protein analysis and sequencing are crucial.
3. Contract Research Organizations (CROs): Companies that provide specialized research services, including advanced analytical and sequencing services, to biopharmaceutical companies and other clients.

Jeff Hawkins, President and Chief Executive Officer

Jeff Hawkins joined Quantum-Si in October 2022. Prior to this role, he served as President and CEO of Truvian Sciences, Inc., where he was responsible for leading the evolution of the company's benchtop blood testing system from concept through late-stage development. Before his tenure at Truvian, Mr. Hawkins led the Reproductive and Genetic Health Business Unit at Illumina, Inc., overseeing the rapid global growth of next-generation sequencing in various markets. He brings over 20 years of experience from leading life science and diagnostics companies and is a co-inventor on 10 issued or pending patents.

Jeff Keyes, Chief Financial Officer

Jeff Keyes serves as the Chief Financial Officer of Quantum-Si. No additional background information regarding founding or managing other companies, selling companies, or a pattern of managing private equity-backed companies is available in the provided search results.

Christian LaPointe, PhD, General Counsel

Christian LaPointe, PhD, has been Quantum-Si's General Counsel since November 2020. Before joining Quantum-Si, Dr. LaPointe held positions as General Counsel at ArcherDX, Inc., a genomics company, and also at Celsee, Inc., a single cell analysis solutions provider.

Todd Rearick, Chief Technology Officer

Todd Rearick has held the position of Chief Technology Officer at Quantum-Si since January 2019. His previous experience includes serving as Chief Technology Officer at Hyperfine Research and holding various roles at Life Technologies and Ion Torrent.

John Vieceli, PhD, Chief Product Officer

John Vieceli, PhD, joined Quantum-Si in December 2022 and currently leads Product Development and Operations. He possesses nearly two decades of experience in building technical teams and successfully bringing early-stage technology to market. Dr. Vieceli previously held leadership roles at several next-generation DNA sequencing companies, including Illumina, Omniome, and Pacific Biosciences.

The key risks to Quantum-Si (QSI) include:

1. High Cash Burn and Limited Commercial Traction: Quantum-Si is characterized by significant negative operating cash flow, substantial net losses, and modest revenue, indicating a high cash burn rate as it remains in a heavy investment phase. This raises concerns about achieving widespread market adoption and a clear path to profitability despite a current cash runway.

2. Execution Risk for New Platforms and Market Adoption Challenges: The company's long-term value is heavily dependent on the successful commercialization and widespread adoption of its proprietary technology, including upcoming platforms like Proteus. There is a risk of slower-than-anticipated market uptake, technical setbacks during the development cycle, or supply chain issues. Challenges in the U.S. academic market due to uncertainties in NIH funding are also impacting sales.

3. Competition and Potential Dilution: Quantum-Si operates in a competitive landscape with established companies that may possess greater financial and marketing resources. While the company currently has a strong cash position, continued losses and high operating expenses could necessitate future capital raises, which would risk diluting existing shareholders.

The clear emerging threat to Quantum-Si is the potential expansion of companies like Oxford Nanopore Technologies into robust, commercially viable single-molecule protein sequencing. Oxford Nanopore Technologies, a leader in real-time DNA/RNA sequencing via nanopores, possesses a core technology (nanopore detection) that is inherently capable of single-molecule analysis. Should they successfully adapt and commercialize their platform for high-throughput, accurate protein sequencing, it would directly compete with Quantum-Si's proprietary single-molecule detection platform designed for next-generation protein sequencing, potentially offering an alternative or superior method that could capture significant market share.

Quantum-Si (symbol: QSI) operates within substantial addressable markets related to proteomics and next-generation protein sequencing.

The total addressable market (TAM) for proteomics is estimated to be approximately $75 billion globally. Another estimate places the global proteomics market at $32.4 billion in 2022, with a projection to reach $72.9 billion by 2028, growing at a compound annual growth rate (CAGR) of 14.6%. The protein sequencing field as a whole is also projected to be a seventy-billion-dollar market.

More specifically, the global protein sequencing market was valued at approximately $2.29 billion in 2025 and is projected to grow to $3.45 billion by 2034, demonstrating a CAGR of 4.72%. North America held the largest share of this market, accounting for 41.48% in 2025, with the U.S. market alone estimated at $0.88 billion in the same year. Other sources estimate the global protein sequencing market at USD 1.39 billion in 2023, growing at a CAGR of 3.7% from 2024 to 2030, with North America leading with a 36.3% revenue share in 2023. Additionally, a report forecasts the protein sequencing market to grow from USD 1.67 billion in 2025 to USD 2.16 billion by 2031 with a 4.35% CAGR, noting North America's 43.12% market share in 2025.

While next-generation sequencing (NGS) is a broader category, it is relevant as Quantum-Si's technology involves next-generation protein sequencing (NGPS). The global next-generation sequencing market size is valued at $15.53 billion in 2025 and is expected to reach around $60.33 billion by 2034. North America was identified as the largest market in 2024 within the broader NGS market.

Quantum-Si (QSI) is focused on several key drivers to accelerate its revenue growth over the next 2-3 years, primarily centered around the commercialization and expansion of its innovative protein sequencing platforms and related consumables.

1. Increased Commercial Adoption of the Platinum Pro System and Instrument Placement Programs: Quantum-Si's strategy involves actively placing its Platinum Pro system in research labs, particularly within the biopharmaceutical and academic sectors. This approach aims to build an installed base that will generate recurring revenue from consumable kits and drive further scientific publications demonstrating the platform's utility.
2. Growth in Consumable Revenue from the Expanding Installed Base: A significant portion of future revenue growth is expected to come from the increased utilization and sales of consumable kits as more Platinum Pro instruments are placed and actively used by customers. The company anticipates a focus on consumable utilization, especially in 2026, as a crucial step before the full commercial ramp of its next-generation platform.
3. Successful Launch and Commercialization of the Proteus Platform: The anticipated launch of the Proteus system, a next-generation protein sequencing technology expected to outperform its predecessor, is a major driver for future revenue. While 2026 is projected as a transition year with limited new capital sales, the company aims for a strong commercial ramp of Proteus in 2027 and beyond, following its expected launch by the end of 2026.
4. Expansion of International Distribution and Focus on Pharma/Biotech Markets: Quantum-Si has been strategically expanding its international distribution network, which included 23 partners as of the first quarter of 2025, and has a key North American distribution agreement with Avantor. The company is also specifically targeting the pharmaceutical and biotech industries, where it has seen a doubling of its opportunity pipeline, indicating a strong growth area.
5. Introduction of New Sequencing and Library Preparation Kits: The development and launch of enhanced product offerings, such as the version 4 Sequencing Kit (expected Q3 2025) and a new version 3 Library Preparation Kit (expected end of 2025), are expected to broaden the capabilities of Quantum-Si's platforms. These innovations are designed to improve proteome coverage and amino acid detection, thereby increasing the appeal of their technology and driving additional consumable sales.

Share Issuance

• Quantum-Si completed a business combination with HighCape Capital Acquisition Corp., a special purpose acquisition company (SPAC), in June 2021. The transaction was valued at approximately $1.46 billion and was expected to generate up to $514 million in gross proceeds.
• As part of the SPAC merger, Quantum-Si secured an oversubscribed $425 million Private Investment in Public Equity (PIPE) from institutional investors.
• Between the fourth quarter of 2024 and the first week of 2025, the company raised over $86 million in capital.

Inbound Investments

• The merger with HighCape Capital Acquisition Corp. (SPAC) represented a significant inbound investment, providing over $500 million to fund Quantum-Si's development and commercialization.
• The $425 million PIPE that was part of the SPAC transaction saw investments from leading institutional firms including Foresite Capital Management, Eldridge, and accounts advised by ARK Invest.

Capital Expenditures

• In the most recent 12-month period (relative to late 2024/early 2025), capital expenditures amounted to -$2.52 million.
• Operating expenses in 2023 were reduced compared to 2022, with a strategic focus on efficient capital deployment towards research and development projects, alongside building commercial capabilities.
• The company anticipates 2026 to be a transition year, with capital focused on preparing for the launch of its Proteus platform.